Bone pain in advanced prostate cancer is often severe, and for many men it affects daily life most. This article is for men with metastatic castration-resistant prostate cancer (mCRPC) - prostate cancer that has spread beyond the prostate and is no longer controlled by standard hormone therapy - and for their families. The key question is: can Lu-177 PSMA therapy, a targeted radioligand treatment, reduce bone pain as part of managing this disease?
The short answer, based on available research, is that it may. For men with PSMA-positive bone metastases, some studies suggest meaningful pain improvement is possible alongside disease control. But results vary, eligibility is not universal, and realistic expectations matter. Here is what the evidence shows.
Why does advanced prostate cancer cause bone pain?
Prostate cancer cells tend to spread to the skeleton before spreading to soft tissue organs. When those cells settle in bone, they disrupt the normal balance between bone breakdown and bone repair. The result is bone lesions - areas of structural damage that irritate nerve endings, weaken the bone, and sometimes press on the spinal cord.
Pain from bone metastases can be constant or intermittent. It is often worse at night. It can flare with movement or pressure. For men with many lesions, discomfort may be widespread across the hips, spine, pelvis, and ribs. Research on pain in castration-resistant prostate cancer with bone metastases identifies this as one of the main drivers of reduced quality of life in mCRPC. Bone disease in this setting tends to be a continuing process, not a single event, as the cancer progresses.
How Lu-177 PSMA therapy targets bone metastases
Lu-177 PSMA therapy - sold under the brand name Pluvicto, or referred to by its full drug name lutetium Lu 177 vipivotide tetraxetan - is a radioligand therapy. A radioligand is a molecule designed to find a specific protein on cancer cells and deliver radiation directly to those cells.
The target in this case is PSMA, or prostate-specific membrane antigen. PSMA is a protein that sits on the surface of most prostate cancer cells. It tends to be expressed at much higher levels on cancer cells than on healthy tissue. A PSMA-PET scan - usually performed with gallium-68 PSMA - confirms whether a patient's tumors have enough PSMA on them for this approach to work before treatment starts.
When lutetium Lu 177 vipivotide tetraxetan is given as an intravenous infusion, it travels through the bloodstream, binds to PSMA-positive cells wherever they are in the body - including in bone - and releases short-range beta radiation. That radiation travels only a few millimeters. The goal is to damage cancer cells while limiting exposure to the surrounding healthy tissue.
Because bone metastases in prostate cancer are often PSMA-positive, this mechanism may allow the therapy to reach lesions in the skeleton that are contributing to pain. That is one reason researchers and clinicians have examined pain outcomes alongside the primary goal of disease control. The US FDA approved lutetium Lu 177 vipivotide tetraxetan in March 2022 for adults with PSMA-positive mCRPC who had received prior androgen receptor pathway inhibitor and taxane-based chemotherapy. The indication has since been expanded further.
What does the evidence say about pain relief?
The VISION trial is the key phase 3 study for this therapy. It enrolled men with PSMA-positive mCRPC who had already progressed through multiple prior lines of treatment. The trial showed that Lu-177 PSMA-617 plus standard of care improved both cancer control and overall survival compared with standard of care alone.
A separate analysis of patient-reported outcomes from the VISION trial looked specifically at pain and quality of life. That Lancet Oncology publication found that men receiving Lu-177 PSMA-617 had a longer time before their pain worsened, compared with men receiving standard of care alone. Men who received the radioligand therapy also maintained better quality-of-life scores for longer. This suggests the treatment both slows disease progression and helps men feel better day to day.
Smaller real-world studies provide more detail on bone pain specifically. A single-centre study of Lu-177 PSMA therapy in mCRPC patients - a large proportion of whom had bone metastases - reported a significant reduction in bone pain in 88% of patients with bone metastases between the first and second treatment cycles. In that same study, 65% of surviving patients reported no pain or only mild pain at their final follow-up visit.
Another study focused on patients with diffuse bone marrow involvement - a more advanced pattern of bone disease where cancer has spread widely through the marrow - found that Lu-177 PSMA therapy produced responses in this group, though outcomes varied based on individual factors including PSMA expression levels and prior treatment history.
These findings matter, but they need context. Study populations differ. Not all patients had the same disease burden, organ function, or level of PSMA expression in their bone lesions. What research reports on average may not match any one patient's experience. To understand who responds and by how much, read Lu-177 PSMA Therapy Does Not Work for Everyone before drawing conclusions about your own case.
Pain flares and realistic timelines
Pain relief from Lu-177 PSMA therapy, when it occurs, usually takes several weeks to become clear. Some men experience a temporary increase in bone pain in the days after the first infusion. This is sometimes called a pain flare. This likely reflects a short-term response as cancer cells are damaged by radiation. It typically settles within one to two weeks.
Meaningful changes in pain are more often apparent after the second or third cycle than after the first. Most oncologists review PSA levels and imaging at around four to six weeks after each cycle to assess whether the therapy is controlling the disease. Pain relief tends to follow a similar pattern - improvement that comes gradually rather than suddenly.
It is also important to understand that not all bone pain in mCRPC comes from active cancer cells. Structural damage to bone - fractures, areas of bone loss, or spinal compression that has already formed - may persist even when the cancer in that area is responding to treatment. This is one reason many patients continue bone-protective medications alongside Lu-177 therapy rather than stopping them.
For a more detailed look at what to expect in the months following treatment - including symptom changes, PSA patterns, and scan timelines - see What to Expect 3-6 Months After Lu-177 PSMA Therapy.
Who is a candidate for this therapy?
Eligibility depends on several factors. The first and most important step is a PSMA-PET scan. If your bone metastases do not express PSMA at a high enough level, the therapy is unlikely to reach and treat those lesions effectively. Not every man with mCRPC has strongly PSMA-positive disease - this is one reason the PET scan is required before treatment, not optional.
Beyond the scan, your care team will assess kidney function and bone marrow reserve, since these tissues receive some radiation exposure during treatment cycles. Your prior treatment history matters too. The original FDA approval required prior androgen receptor pathway inhibitor therapy and taxane-based chemotherapy. Later expansions have broadened who may qualify. If an earlier assessment said you were not eligible, ask for a current review under the updated criteria.
To understand what your scan results mean for eligibility decisions, read What Your PSMA-PET Results Mean for Lu-177 Eligibility to see the key thresholds and what happens if your results are borderline.
If you are based in a country where this therapy is not available, or if you want a specialist team to review your scans and case records before you travel for treatment, you can request a Lu-177 eligibility review through Art of Healing Cancer. The team can assess your PSMA-PET findings and advise on whether your case meets the criteria - and what the realistic next steps are if it does not.
Managing bone pain alongside Lu-177 therapy
Lu-177 PSMA therapy addresses the cancer driving bone disease. Several other approaches work on the bone structure itself. Many men use both types of support at the same time, under guidance from their care team.
Bone-protective agents - bisphosphonates such as zoledronic acid, and denosumab, a RANK-ligand inhibitor - are commonly used in mCRPC to reduce the risk of fractures and spinal cord compression. They may also reduce some bone pain by strengthening the bone structure. Your oncologist will advise whether to continue these during Lu-177 treatment based on your kidney function and overall health status.
External beam radiation to a specific painful bone site can provide faster local relief than any systemic therapy. This targeted, pain-relieving approach treats one area at a time and can sometimes be used alongside systemic treatment, though sequencing decisions depend on your clinical team and the specifics of your disease.
Pain medication - from over-the-counter pain relievers for mild discomfort to prescription opioids for more severe pain - remains an essential tool for day-to-day symptom management. Your care team should be reviewing and adjusting your pain control at each visit, not just your scan and blood results.
Some men also look at over-the-counter options to support their bone and joint health during treatment. Always check with your oncologist or care team before starting any new supplement during active cancer treatment.
Questions to ask your care team
- Does my PSMA-PET scan show enough PSMA expression in my bone lesions to make this therapy a reasonable option?
- Are my kidney function and blood counts within range for Lu-177 treatment?
- Should I continue bone-protective medication during and after treatment cycles?
- Is targeted radiation to a specific, particularly painful bone site an option alongside systemic therapy?
- How will you track whether the treatment is working - and over what time period should I expect to see changes?
- If Lu-177 PSMA therapy is not suitable for my case, what other approaches might address my bone pain?
When to talk to your doctor
If bone pain is worsening, is no longer controlled on your current medication, or is significantly affecting your sleep or ability to move, bring this to your oncologist at your next appointment - or sooner if the pain is severe or sudden. Ask whether a PSMA-PET scan is appropriate if you have not had one recently, since it is the necessary first step toward determining whether Lu-177 PSMA therapy is a realistic option for you. If you want to begin that process or seek a specialist review of your eligibility, you can reach out through the Lutetium Therapy contact page. If Lu-177 therapy is not suitable for you, a second opinion on alternative treatment options is also available through the same contact.
This article is for general information and is not a substitute for medical advice. Always consult your oncologist or care team about your specific situation.
Frequently asked questions
Does Lu-177 PSMA therapy specifically treat bone metastases, or just the cancer overall?
Lu-177 PSMA therapy does not treat bone as a tissue - it targets PSMA, a protein expressed on prostate cancer cells. When bone metastases carry high PSMA expression, the radioligand may reach and damage those specific cancer cells within bone. This can reduce the activity driving bone disease and, in some patients, lead to pain relief over time. It works through the cancer, not on the bone structure itself. Bone-protective medications like bisphosphonates or denosumab are often used alongside Lu-177 therapy to address the structural side of bone disease.
How soon after starting Lu-177 PSMA therapy might bone pain improve?
Pain improvement, when it occurs, is usually gradual rather than immediate. Some men experience a temporary increase in pain - sometimes called a pain flare - in the days after the first infusion. This typically settles within one to two weeks. Meaningful relief is more often reported after the second or third cycle than after the first. Oncologists generally assess treatment response at around four to six weeks after each cycle, and pain trends tend to follow a similar timeline.
Can I still receive Lu-177 PSMA therapy if I have many bone metastases or widespread bone disease?
Having multiple bone metastases does not automatically disqualify someone. Studies have included patients with heavy bone involvement, including those with diffuse bone marrow disease, and some responses were observed. However, the extent of bone marrow involvement is assessed carefully, because significant bone marrow disease can affect the body's tolerance to treatment and increase the risk of blood count side effects. A specialist review of your scans and blood results is needed to determine whether your specific level of bone involvement falls within acceptable limits.
Should I continue bisphosphonates or denosumab while receiving Lu-177 PSMA therapy?
Most oncologists continue bone-protective medications such as zoledronic acid or denosumab during Lu-177 therapy. These medications protect against fractures and other structural complications of bone metastases. They do not treat the cancer but work alongside systemic therapy. The decision depends on your kidney function and individual health status. Always follow your oncologist's specific guidance on this, as stopping or starting these medications requires clinical judgement.
What if my PSMA-PET scan shows low PSMA expression in my bone metastases?
Low or absent PSMA expression in bone lesions means those specific lesions are unlikely to be well targeted by Lu-177 PSMA therapy. Your oncologist may consider other approaches, such as external beam radiation to specific painful sites, bisphosphonates or denosumab for bone protection, or other systemic therapies. A specialist eligibility review can help clarify whether your scan results are strong enough to proceed with radioligand therapy or whether a different approach would better fit your case.
Is pain relief from Lu-177 PSMA therapy permanent?
Pain relief associated with Lu-177 PSMA therapy is linked to how well the therapy controls the underlying cancer. If the cancer responds to treatment, pain may remain low for as long as the disease is being controlled. If the cancer eventually progresses again, symptoms may return. Lu-177 PSMA therapy is not described as a cure. However, meaningful disease control over several months can substantially improve daily quality of life during that period, which is a clinically significant goal in mCRPC.
